References
- Cunningham AL, Breuer J, Dwyer DE, Gronow DW, Helme RD, Litt JC, Levin MJ, Macintyre CR. The prevention and management of herpes zoster. Med J Aust. 2008;188:171–76. doi:https://doi.org/10.5694/j.1326-5377.2008.tb01566.x.
- Forbes HJ, Thomas SL, Langan SM. The epidemiology and prevention of herpes zoster. Curr Dermatol Rep. 2012;1:39–47. doi:https://doi.org/10.1007/s13671-011-0004-4.
- MacIntyre R, Stein A, Harrison C, Britt H, Mahimbo A, Cunningham A. Increasing trends of herpes zoster in Australia. PLoS One. 2015;10:e0125025. doi:https://doi.org/10.1371/journal.pone.0125025.
- Johnson RW, Dworkin RH. Treatment of herpes zoster and postherpetic neuralgia. BMJ. 2003;326:748–50. doi:https://doi.org/10.1136/bmj.326.7392.748.
- Langan SM, Minassian C, Smeeth L, Thomas SL. Risk of stroke following herpes zoster: a self-controlled case-series study. Clin Infect Dis. 2014;58:1497–503. doi:https://doi.org/10.1093/cid/ciu098.
- Minassian C, Thomas SL, Smeeth L, Douglas I, Brauer R, Langan SM. Acute cardiovascular events after herpes zoster: a self-controlled case series analysis in vaccinated and unvaccinated older residents of the United States. PLoS Med. 2015;12:e1001919. doi:https://doi.org/10.1371/journal.pmed.1001919.
- Zhang Y, Luo G, Huang Y, Yu Q, Wang L, Li K. Risk of stroke/transient ischemic attack or myocardial infarction with herpes zoster: a systematic review and meta-analysis. J Stroke Cerebrovasc Dis. 2017;26:1807–16. doi:https://doi.org/10.1016/j.jstrokecerebrovasdis.2017.04.013.
- Erskine N, Tran H, Levin L, Ulbricht C, Fingeroth J, Kiefe C, Goldberg RJ, Singh S. A systematic review and meta-analysis on herpes zoster and the risk of cardiac and cerebrovascular events. PLoS One. 2017;12:e0181565. doi:https://doi.org/10.1371/journal.pone.0181565.
- Stein AN, Britt H, Harrison C, Conway EL, Cunningham A, Macintyre CR. Herpes zoster burden of illness and health care resource utilisation in the Australian population aged 50 years and older. Vaccine. 2009;27:520–29. doi:https://doi.org/10.1016/j.vaccine.2008.11.012.
- Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, Arbeit RD, Simberkoff MS, Gershon AA, Davis LE, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352:2271–84. doi:https://doi.org/10.1056/NEJMoa051016.
- ZOSTAVAX® (Zoster Vaccine Live) [prescribing information]. Whitehouse Station (NJ): Merck & Co., Inc.; 2019 [accessed 2019 Jun 12]. https://www.merck.com/product/usa/pi_circulars/z/zostavax/zostavax_pi2.pdf.
- Morrison VA, Johnson GR, Schmader KE, Levin MJ, Zhang JH, Looney DJ, Betts R, Gelb L, Guatelli JC, Harbecke R, et al. Long-term persistence of zoster vaccine efficacy. Clin Infect Dis. 2015;60:900–09. doi:https://doi.org/10.1093/cid/ciu918.
- Tseng HF, Harpaz R, Luo Y, Hales CM, Sy LS, Tartof SY, Bialek S, Hechter RC, Jacobsen SJ. Declining effectiveness of herpes zoster vaccine in adults aged ≥60 years. J Infect Dis. 2016;213:1872–75. doi:https://doi.org/10.1093/infdis/jiw047.
- Klein NP, Bartlett J, Fireman B, Marks MA, Hansen J, Lewis E, Aukes L, Saddier P. Long-term effectiveness of zoster vaccine live for postherpetic neuralgia prevention. Vaccine. 2019;37:5422–27. doi:https://doi.org/10.1016/j.vaccine.2019.07.004.
- ZOSTAVAX® (Zoster Virus Vaccine Live [Oka/Merck] Refrigerator stable) [Australian product information]. Macquarie Park (NSW): Merck Sharp & Dohme (Australia) Pty Limited; 2019 [accessed 2019 Jun 12]. https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-01547-3&d=201906121016933.
- National Centre for Immunisation Research and Surveillance (NCIRS). Evaluation of the National Shingles vaccination program process and early impact evaluation. Final Report. 2019 Mar 1 [accessed 2019 Jun 7]. http://ncirs.org.au/sites/default/files/2019-04/Shingles%20Program%20Evaluation%20Report_1%20March%202019_Final%20for%20web.pdf.
- Australian Bureau of Statistics. 3101.0 – Australian demographic statistics. TABLE 59. Estimated Resident Population By Single Year Of Age, Australia; 2018 Dec [accessed 2019 Aug 1]. https://www.abs.gov.au/AUSSTATS/[email protected]/DetailsPage/3101.0Dec%202018?OpenDocument.
- Leeb A, Regan AK, Peters IJ, Leeb C, Leeb G, Effler PV. Using automated text messages to monitor adverse events following immunisation in general practice. Med J Aust. 2014;200:416–18. doi:https://doi.org/10.5694/mja13.11166.
- Department of Health, Commonwealth of Australia. National immunisation strategy for Australia 2019–2024. 2019 Feb 17 [accessed 2019 Sep 20]. https://www.health.gov.au/resources/publications/national-immunisation-strategy-for-australia-2019-to-2024.
- Amirthalingam G, Andrews N, Keel P, Mullett D, Correa A, de Lusignan S, Ramsay M. Evaluation of the effect of the herpes zoster vaccination programme 3 years after its introduction in England: a population-based study. Lancet Public Health. 2018;3:e82–e90. doi:https://doi.org/10.1016/S2468-2667(17)30234-7.
- Zhang D, Johnson K, Newransky C, Acosta CJ. Herpes zoster vaccine coverage in older adults in the U.S., 2007–2013. Am J Prev Med. 2017;52:e17–e23. doi:https://doi.org/10.1016/j.amepre.2016.08.029.
- Centers for Disease Control and Prevention. Vaccination coverage among adults in the United States, National health interview survey. 2016 [accessed 2019 Jun 13]. https://www.cdc.gov/vaccines/imz-managers/coverage/adultvaxview/pubs-resources/NHIS-2016.html.
- Hurley LP, Harpaz R, Daley MF, Crane LA, Beaty BL, Barrow J, Babbel C, Marin M, Steiner JF, Davidson A, et al. National survey of primary care physicians regarding herpes zoster and the herpes zoster vaccine. J Infect Dis. 2008;197(Suppl 2):S216–223. doi:https://doi.org/10.1086/522153.
- Hurley LP, Lindley MC, Harpaz R, Stokley S, Daley MF, Crane LA, Dong F, Beaty BL, Tan L, Babbel C, et al. Barriers to the use of herpes zoster vaccine. Ann Intern Med. 2010;152:555–60. doi:https://doi.org/10.7326/0003-4819-152-9-201005040-00005.
- High KP. Overcoming barriers to adult immunization. J Am Osteopath Assoc. 2009;109:S25–28.
- Williams WW, Lu PJ, O’Halloran A, Kim DK, Grohskopf LA, Pilishvili T, Skoff TH, Nelson NP, Harpaz R, Markowitz LE, et al. Surveillance of vaccination coverage among adult populations – united States, 2015. MMWR Surveill Summ. 2017;66:1–28. doi:https://doi.org/10.15585/mmwr.ss6611a1.
- Litt J, Cunningham T, Van Buynder P Update on herpes zoster. Healthed expert monograph, issue 18. 2018 [accessed 2019 Oct 2]. https://www.healthed.com.au/monographs/update-herpes-zoster/.
- Public Health England. Herpes zoster (shingles) immunisation programme 2017 to 2018: evaluation report. Evaluation of the fifth year of the shingles vaccination programme in England from 2017 to 2018. Health Protection Report. Volume 12 Number 42; 2018.
- Kerzner B, Murray AV, Cheng E, Ifle R, Harvey PR, Tomlinson M, Barben JL, Rarrick K, Stek JE, Chung MO, et al. Safety and immunogenicity profile of the concomitant administration of ZOSTAVAX and inactivated influenza vaccine in adults aged 50 and older. J Am Geriatr Soc. 2007;55:1499–507. doi:https://doi.org/10.1111/j.1532-5415.2007.01397.x.
- Litt JCB, Kim S, Woodman R, MacIntyre R, Cunningham T. Australian zoster study: GP and patient views about herpes zoster (shingles), its complications, and the likely acceptance of a zoster vaccine (Zostavax). Int J Infect Dis. 2014;21(Suppl 1):436–37. doi:https://doi.org/10.1016/j.ijid.2014.03.1320.
- Walker JL, Andrews NJ, Amirthalingam G, Forbes H, Langan SM, Thomas SL. Effectiveness of herpes zoster vaccination in an older United Kingdom population. Vaccine. 2018;36:2371–77. doi:https://doi.org/10.1016/j.vaccine.2018.02.021.
- Jardine A, Conaty SJ, Vally H. Herpes zoster in Australia: evidence of increase in incidence in adults attributable to varicella immunization? Epidemiol Infect. 2011;139:658–65. doi:https://doi.org/10.1017/S0950268810001949.
- Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open. 2014;4:e004833. doi:https://doi.org/10.1136/bmjopen-2014-004833.
- Reynolds MA, Chaves SS, Harpaz R, Lopez AS, Seward JF. The impact of the varicella vaccination program on herpes zoster epidemiology in the United States: a review. J Infect Dis. 2008;197(Suppl 2):S224–227. doi:https://doi.org/10.1086/522162.